Literature DB >> 10626135

Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group.

M A Pfaller1, R N Jones, G V Doern, J C Salazar.   

Abstract

The minimum inhibitory concentrations of six broad-spectrum beta-lactam antimicrobial agents were determined in 1998 by use of the Etest versus a total of 823 bacteria in 11 Colombian hospital laboratories. These data were compared with results of a similar study conducted in 1997. The organisms tested included 532 recent clinical isolates of Enterobacteriaceae, 108 Pseudomonas aeruginosa, 94 Acinetobacter species, and 89 oxacillin-susceptible Staphylococcus aureus. Extended-spectrum beta-lactamase production was noted among 27.8 to 33.9% of Escherichia coli isolates and 41.7 to 46.7% of Klebsiella spp. isolates. Hyperproduction of Amp C cephalosporinases was observed with 10.5 to 31.4% of isolates of Enterobacter spp., Serratia spp., and Citrobacter spp. An increase in resistance to all of the beta-lactams was observed among Enterobacteriaceae, Acinetobacter spp. and P. aeruginosa when 1998 results were compared with those obtained in 1997. The overall rank order of activity of the six beta-lactams tested in 1998 versus all clinical isolates was imipenem (93.2% susceptible) > cefoperazone/sulbactam (84.1%) > cefepime (80.9%) > ceftazidime (70.7%) > aztreonam (65.7%) > cefotaxime (65.6%). In contrast, the rank order of these same agents tested against a similar collection of Colombian isolates in 1997 was imipenem (96.6% susceptible) > cefepime (93.6%) > cefoperazone/sulbactam (90.5%) > cefotaxime (74.9%) > aztreonam (74.3%) > ceftazidime (73.2%).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626135     DOI: 10.1016/s0732-8893(99)00077-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Evaluation of Etest for susceptibility testing of multidrug-resistant isolates of Mycobacterium tuberculosis.

Authors:  M H Hazbón; M del Socorro Orozco; L A Labrada; R Tovar; K A Weigle; A Wanger
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 2.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

3.  Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine.

Authors:  R Someshwaran; K Gnana Prakash; Shreeram A Deshpande; Anbu N Aravazhi
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 4.  Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Authors:  Mark E Rupp; Paul D Fey
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Third generation cephalosporin use in a tertiary hospital in Port of Spain, Trinidad: need for an antibiotic policy.

Authors:  Lexley M Pinto Pereira; Marjorie Phillips; Hema Ramlal; Karen Teemul; P Prabhakar
Journal:  BMC Infect Dis       Date:  2004-12-15       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.